-
StockWatch: MacroGenics Shares Crater after Trial Deaths
12 May 2024 14:29 GMT
… treatment being co-developed with Amgen (AMGN).
CytomX CEO and … McCarthy, sending CytomX shares tailspinning. The shares began nosediving 32% in … will inform discussions with Amgen toward launching Phase Ib … have the conversation with Amgen later in the year …
-
CytomX’s Amgen-partnered T cell engager yields mixed Phase 1 data
09 May 2024 12:14 GMT
CytomX and Amgen’s T cell engager showed … tumors, sending the biotech’s shares down 37% even as analysts …
-
Global Chest Drainage Catheters Market to Exhibit Growth at a CAGR of ~5% by 2030 | DelveInsight
13 May 2024 17:00 GMT
… chest drainage catheters companies’ market shares, challenges, chest drainage catheters market … , Honya Medical Inc, AstraZeneca, Helixmith, Amgen, Angionetics, Xylocor Therapeutics, Regio Biosciences …
-
The 3 Best Dow Stocks to Buy in May 2024
13 May 2024 15:25 GMT
… dropped in that time. Meanwhile, Amgen (NYSE:AMGN), Caterpillar (NYSE:CAT … raised its rating on the shares to “Buy,” citing … the shares have climbed almost 17% in the last month.
Amgen ( … AMGN)
Source: Shutterstock
Amgen CEO Robert Bradway …
-
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
13 May 2024 11:00 GMT
… to the collaboration agreement with Amgen which commenced in May 2023 … Company had issued and outstanding shares of 47,904,737, … an additional 4,958,068 shares of voting common stock, … (0.93
)
Weighted average common shares outstanding—basic and diluted (2 …
-
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2024 Earnings Call Transcript
10 May 2024 17:16 GMT
… olpasiran, being conducted by Amgen. We originally licensed olpasiran, … previously called AROLPA, to Amgen in 2016 and then … additional $375 million from Amgen and $110 million from … fully diluted weighted average shares outstanding. This compares with …
-
World PEGylated Proteins Analysis Report 2023-2028: Increasing Utilization of Protein Drugs in Hematology and Oncology Bodes Well for the Market - ResearchAndMarkets.com
10 May 2024 17:12 GMT
… landscape, including companies' market shares, business segments, financials and product … venture funding outlook
Company Profiles
Amgen Inc.
F. Hoffmann-La Roche …
-
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
09 May 2024 20:31 GMT
… avutometinib plus defactinib with Amgen’s G12C inhibitor, LUMAKRAS … avutometinib in combination with Amgen’s G12C inhibitor, LUMAKRAS … clinical collaborations with Amgen and Mirati to … .94)(1
)
Weighted average common shares outstanding used in computing:
…
-
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
09 May 2024 20:08 GMT
… $1.8 million decrease in Amgen revenue, due to work progressing …
)
$
(12,552
)
Weighted-average shares used to compute basic and … all the issued and outstanding shares of common stock of Alpine … of an offer to sell shares of Alpine, nor is it …
-
Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
09 May 2024 20:01 GMT
… ® is a registered trademark of Amgen, Inc. Humira® is a … .96
)
Weighted-average number of shares used in computing net income … 749,306
79,268,853
Shares used in computing diluted net … (0.32
)
$
(0.75
)
Shares used in computing basic and …